EP2753630A1 - Dérivés du 4-methylcatechol et utilisations desdits dérivés - Google Patents

Dérivés du 4-methylcatechol et utilisations desdits dérivés

Info

Publication number
EP2753630A1
EP2753630A1 EP12756072.0A EP12756072A EP2753630A1 EP 2753630 A1 EP2753630 A1 EP 2753630A1 EP 12756072 A EP12756072 A EP 12756072A EP 2753630 A1 EP2753630 A1 EP 2753630A1
Authority
EP
European Patent Office
Prior art keywords
glycoside
aglycone
residue
methylphenoxy
ethylphenoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP12756072.0A
Other languages
German (de)
English (en)
Inventor
Hans-Michael Thiede
Wolfgang Kehr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
THANARES GmbH
Original Assignee
THANARES GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by THANARES GmbH filed Critical THANARES GmbH
Publication of EP2753630A1 publication Critical patent/EP2753630A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Definitions

  • the invention relates to novel phenoxy derivatives with glycosidically bound sugar residues which are used in
  • degenerative diseases hypertension, atherosclerosis, venous insufficiency, diabetes mellitus, osteoporosis, cataract and photoaging of the skin are suitable, pharmaceutical
  • compositions containing such compounds are provided.
  • compositions and methods for preparing such compounds are provided.
  • NGF Neurotrophins Nerve Growth Factor
  • BDNF Brain Derived Nerve Growth Factor
  • GDNF Glia Derived Nerve Growth Factor
  • 4-MC stimulates the phosphoinositol 3-kinase / AKT and the Nrf2-ARE signal transduction pathway, thereby activating the expression of heme oxygenase, which in turn increases the formation of bilirubin and carbon monoxide in addition to iron in response to oxidative stress of the
  • diabetes mellitus The complications of diabetes mellitus include diabetic neuropathy, which affects 30-50% of diabetics, making them the most common peripheral
  • Sensitivity disorders with and without circulatory disorders develop into a clinical picture which often leads to an amputation of the lower extremity. Due to this diagnosis, about 30,000 lower limb amputations are performed each year in Germany alone
  • neurotrophins such as Glia Cell-derived Neurotrophic Factor (GDNF), neurotrophin 3 and NGF in the intestine
  • GDNF Glia Cell-derived Neurotrophic Factor
  • NGF NGF-derived Neurotrophic Factor
  • induced diabetic neuropathy can be favorably influenced by the administration of 4-MC (Hanaoka Y. et al., J Neurol Sci. 1994 Mar; 122 (1): 28-32).
  • 4-MC Haoka Y. et al., J Neurol Sci. 1994 Mar; 122 (1): 28-312.
  • gentamycin - induced ototoxicity by 4 - MC is antagonized via stimulation of NGF and other neurotrophins.
  • alkylcatechols and their derivatives also have preventive and therapeutic effects in humans in various forms of neuropathies, as in diabetic neuropathy, but also in
  • 4-MC has neuroprotective effects by activating heme oxigenase-1 expression, particularly against harmful oxidative stress (Furukawa Y. et al., Biomedical Res 2010; 31: 45-52). 4-MC also stimulates the mitogen-activated protein kinase (MAPK / ERK1 / 2), the
  • CREB plays an important role in both nerve growth and neuronal survival.
  • Oxidative stress is associated with the demise of
  • AD antioxidant responsive element
  • Nrf2 Transcription factor NF-E2 -related factor 2 (Nrf2), which binds to ARE, protects neurons from oxidative stress-induced cell death (Johnson JA et al., Ann NY acad Sci. ' 2008; 1147: 61-69). 4-MC activates Nrf2 and may also act neuroprotective via this signal transduction pathway (Satoh T. et al., Biochem. Biophys Res. Commun., 2009; 379: 537-341).
  • Alkyl catechols such as 4-MC have additional
  • Cytokines such as TNF from microglia, which are associated with clear neuroprotective effects. (Zheng LT et al., Eur J Phormacol., 2008; 588: 106-113). These protective effects can be used to treat neurodegenerative diseases associated with pronounced activation of the microglia. The maintenance or improvement of cognitive functions is for demented patients, eg patients with morbus
  • 4-MC also improved rat spatial learning and memory, an effect in which BDNF appears to be involved because coadministration of BDNF antibodies abolished the effect of 4-MC.
  • O-methyl metabolites of alkyl catechols such as 2-methoxy-4-ethylphenol, have neuroprotective effects
  • Diabetes mellitus Inhibition of Non-oxidative AGE (Advanced Glycation End Product) Formation by 4-MC and DOPAC has been demonstrated in Pashikanti S. et al., Free Radical Biol Med. 2009 Dec
  • Melanoma / basalioma 4 -MC inhibits the proliferation of melanoma cells ohrie's
  • Metabolites of alkyl catechols such as 2-methoxy-4-methylphenol (creosol) and 2-methoxy-4-ethylphenol, which are produced by the
  • osteoporosis an experimental model of postmenopausal osteoporosis, is thought to be due to inhibition of bone-degrading osteoclasts in conjunction with an anti-oxidative effect on bone growth promoting osteoblasts (Moriguchi N. et al., Biochem Pharmacol 2007; 73: 385-393).
  • hydroxytyrosol 3,4-dihydroxyphenylethanol
  • ovariectomized rats has also been described (Puel C et al., J Agric Food Chem. 2008; 56: 9417-9422).
  • the invention is therefore based on the technical problem of specifying means which are suitable as mentioned above To prevent or treat diseases by establishing a high physiological availability of 4 MC or possibly its physiologically active derivatives.
  • Rl may alternatively be vicinal to the group -O-R2 but not a compound selected from the group consisting of 5-allyl catechol bis ( ⁇ -D-glucopysranoside), 3-OaD glucopyranosyl -Dopamine, 4-OaD-glucopyranosyl-dopamine, 3-O- ⁇ -D-glucopyranosyl-DOPA, 4-O- ⁇ -D-glucopyranosyl-DOPA, 3-O- ⁇ -D-manopyranosyl-dopamine, 4-O-aD -manopyranosyl-dopamine, 3-0- ⁇ -D-galactopyranosyl-dopamine, 4-0-aD-galactopyranosyl-dopamine, 3-0-aD-2-deoxyglucopyranosyl-dopamine, 4-0-aD-2-deoxyglucopyranosyl-dopamine, 4-0-aD-2-deoxy
  • R 2 is a residue that can not be split off microbiologically, which radical is coupled directly to the aromatic ring of formula I (that is, without the -0-atom shown in the formula I) and R3 is -H, wherein R2 contains at least one ionizable functional group, or physiologically acceptable salts of such compounds.
  • Physiologically acceptable salts include as counter ions for ionic compounds, for example Mg ++ , Pb ++ , Mn ++ , Ca ++ ,
  • the galenic preparation can take place in such a way that a metabolism in the stomach or in the small intestine practically does not take place.
  • Microbiota from these compounds increases 4 -MC arises.
  • R2 contains at least one ionizable functional group, it can be in particular quercetin derivatives, preferably
  • Quercetin sulfates wherein the sulfate group is bonded to one of the - OH group-bearing C atom of the quercetin molecule, or a glucoside, wherein the sugar residue on the -O atom of one of the -OH groups of the quercetin molecule is glycosidically bound.
  • Sugars are the sugars mentioned below in other contexts. They can be simple, 2-fold, 3-fold, 4-fold, or 5-fold, the same or different. Likewise, the sulfate groups can be 1-fold, 2-fold, 3-fold, 4-fold, or 5-fold. It is also possible to combine sugar group (s) and sulfate group (s) as desired.
  • Compound is quercetin-3-sulfate.
  • Other examples include all of the compounds and substances mentioned in the document DE patent application 10 2007 029 042.1, for example:
  • R is selected from -H, -OH, -CH 3, - CH 2 -CH 3, -CH 2 -COOH, or -CH 2 -COO ". It is further preferred if R 2 and R 3, identical or different, are selected from -OR 7, -O-CO-R 8 and L-sugar radical, in D or L form, as furanose, pyranose, in each case in alpha or beta. Form, or as aldehyde,
  • glycosidic -O-bridge Typically, the glycosidic bond in position 2 of the
  • Be arranged sugar molecule can also be set up at one of the 3, 4, or 5 positions of the sugar molecule.
  • the -O- bridge it is also possible to provide an -S- or -Se bridge as the glycosidic bond, and thus to be thioglycosides or selenoglycosides.
  • -OH groups which may instead be -SH or -Se groups.
  • radicals R 2 or R 3 are each an L-sugar radical and the other radical is one of said non-glycosidic radicals (monoglycosides), or that both radicals R 2 and R 3 are each an L-sugar radical, the same or
  • R2 is selected from one of the sugar residues of L-rhamnose, L-lactulose, L-xylose, L-arabinose, L-mannose, L-glucose and R3 -OH, or vice versa. Examples of compounds according to the invention, without, however, being limiting, are given below by way of illustration.
  • Glycoside of L-xylose, where the aglycone residue is 4- is (carboxymethyl) -2-methoxyphenoxy,
  • Glycoside of L-glucose, with the aglycone residue 5 is (carboxymethyl) -2-hydroxyphenoxy,
  • Furanose form or the pyranose form may be present.
  • glycosidic -O- or -S- or -Se-
  • This is bound on the one hand to the phenyl ring and on the other hand to one of the C atoms of the sugar numbered 2, 3, or 4.
  • the sugar residues may also dimers or oligomers,
  • the invention further relates to a pharmaceutical
  • composition comprising a compound of the invention and galenic excipients and / or carriers, prepared for oral administration, wherein the oral preparation
  • stable designates that less than 50% by weight, in particular less than 20% by weight, preferably less than 5% by weight, of the added compound is decomposed in the stomach or the small intestine, or that the Such materials are known to the person skilled in the art, for example: anionic copolymers based on methacrylic acid and methyl methacrylate, such as Eudragit, in particular Eudragit S, galactomannan, in particular
  • guar galactomannan guar galactomannan
  • dextran ethylated guar gum
  • Lauric acid amylose, especially cross-linked amylose, chitosan, cross-linked chondroitin, pectin (Bauer Kh., Colonic drug delivery: review of material trends, American Pharmaceutical Review 2001, 4, 8-16).
  • a pharmaceutical composition of the invention contains the compound of the invention in a physiologically effective dose.
  • a dose of a dosage unit is typically, but not necessarily, in the range of 0.1 mg to 2,000 mg, preferably in the range of 1 mg to 500 mg, in particular in the range of 10 mg to 200 mg.
  • the invention also relates to a process for the preparation of a pharmaceutical composition according to the invention, wherein a compound of the invention mixed in physiologically effective dose with pharmaceutical excipients and carriers and to a predetermined dosage form
  • Suitable solid or liquid pharmaceutical preparation forms are, for example, granules, powders, dragees, tablets, (micro) capsules, suppositories, syrups, juices, suspensions, emulsions and preparations with protracted release of active ingredient
  • Carrier blasting, binding, coating, swelling, lubricating or lubricating, flavoring, sweetening and
  • Solubilizer find use. It is also possible.
  • the active ingredient in preferably biologically, for example in the large intestine, but not stomach or small intestine, degradable
  • Auxiliary substances are, for example, sodium carbonates,
  • vegetable oils such as cod liver oil, sunflower, peanut or sesame oil, polyethylene glycols and solvents such as sterile water and monohydric or polyhydric alcohols,
  • a pharmaceutical composition according to the invention can be prepared by at least one substance used according to the invention in
  • Suitable active ingredients, additives or excipients mixed with a defined dose and prepared for the desired dosage form are polyglycols, water and buffer solutions.
  • suitable Buffer substances are, for example, ⁇ , ⁇ '-dibenzylethylenediamine, diethanolamine, ethylenediamine, N-methylglucamine, N-benzylphenethylamine, diethylamine, phosphate, sodium bicarbonate, or sodium carbonate.
  • Physiologically acceptable salts are salts with inorganic or
  • organic acids e.g. Lactic acid, hydrochloric acid,
  • Ethylenediamine, or with amino acids such as arginine, lysine, glutamic acid, etc. or with inorganic salts such as CaCl 2 , NaCl or their free ions, such as Ca 2+ , Na + , Pb ++ , Cl ⁇ , S0 4 2 " or corresponding salts and free ions of Mg ++ or Mn ++ , or combinations thereof, are prepared by standard methods.
  • the invention relates to the use of a compound of the invention for the preparation of a
  • compositions in particular for the prophylaxis or treatment of a disease of humans or animals from the group consisting of peripheral and autonomic neuropathies, central nervous degenerative diseases, hypertension,
  • Atherosclerosis venous insufficiency, diabetes mellitus,
  • the invention relates to a method for
  • Prophylaxis or treatment of a human or animal disease from the group consisting of peripheral and autonomic neuropathies, central nervous degenerative diseases,
  • Suitable daily doses are, for example, 0.3 mg to 6,000 mg, preferably 1 mg to 1,000 mg, in particular 10 mg to 500 mg.
  • the invention relates to a method for
  • Protective group compound is reacted, wherein OH groups of the sugar are protected, optionally leaving an OH group of the sugar without protective group, wherein the sugar is then reacted with a compound of formula III
  • R31 and R32 are selected from -OH and -O-R35 having R35 -H or C1-C6 alkyl, linear or branched, saturated or unsaturated, with the proviso that at least one of R31 or R32 is -OH, wherein R33 and R34, same or different, may have the same meaning as R1 or is -CHO,
  • Reaction conditions as well as the elimination of protective groups and their reaction conditions are the embodiments independently of their concrete embodiment removed.
  • reaction solution is extracted with 1 M aqueous NaOH (1 ⁇ 500 ml).
  • organic phase is dried over Na 2 S0 4 , filtered and in vacuo
  • Example 1.4 Further Substances According to the Invention The following are synthesis routes of further inventive
  • the substance used according to the invention was alternatively prepared without coat and with such a coat and used for comparative experiments.
  • Ratio 1 2 in isopropyl alcohol, available from Evonik Industries).
  • the dosage form was prepared by compressing tablet cores with different amounts of the active ingredients (20 mg to 250 mg) and the excipients 6 mg magnesium stearate and 600 mg Ludipress (93% lactose plus 3.5% Kollidon plus Kollidon CL, available from BASF).

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

L'invention concerne des dérivés phénoxy contenant des résidus de sucre à liaison glycosidique, des compositions pharmaceutiques contenant lesdits composés, les utilisations desdits composés et desdites compositions, ainsi que des procédés de préparation desdits composés et desdites compositions pharmaceutiques.
EP12756072.0A 2011-09-07 2012-08-06 Dérivés du 4-methylcatechol et utilisations desdits dérivés Withdrawn EP2753630A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102011112496A DE102011112496A1 (de) 2011-09-07 2011-09-07 4-Methylcatecholderivate und deren Verwendung
PCT/DE2012/000790 WO2013034119A1 (fr) 2011-09-07 2012-08-06 Dérivés du 4-methylcatechol et utilisations desdits dérivés

Publications (1)

Publication Number Publication Date
EP2753630A1 true EP2753630A1 (fr) 2014-07-16

Family

ID=46801260

Family Applications (1)

Application Number Title Priority Date Filing Date
EP12756072.0A Withdrawn EP2753630A1 (fr) 2011-09-07 2012-08-06 Dérivés du 4-methylcatechol et utilisations desdits dérivés

Country Status (4)

Country Link
US (2) US20160347782A1 (fr)
EP (1) EP2753630A1 (fr)
DE (1) DE102011112496A1 (fr)
WO (1) WO2013034119A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3466417A1 (fr) * 2017-10-04 2019-04-10 Sorbonne Université Composés pour la prévention et le traitement de conditions liées à l'intolérance au glucose et de l'obésité
CR20200225A (es) 2017-11-24 2020-07-25 H Lundbeck As Nuevos fármacos de catecolamina para uso en el tratamiento de la enfermedad de parkinson
US11111263B2 (en) 2019-05-20 2021-09-07 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11130775B2 (en) 2019-05-20 2021-09-28 H. Lundbeck A/S Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11104697B2 (en) 2019-05-20 2021-08-31 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1- propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11168056B2 (en) 2019-05-20 2021-11-09 H. Lundbeck A/S Process for the manufacturing of (6aR,10aR)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxolo[4′,5′:5,6]benzo[1,2-G]quinoline and (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[G]quinoline-6,7-diol

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2156777B1 (es) * 1999-12-22 2002-03-01 Consejo Superior Investigacion Derivados de beta-glicosil dopamina y sus sales como agentes potenciales de reposicion de dopamina en cerebro y su procedimiento de obtencion
JP4430374B2 (ja) * 2003-10-23 2010-03-10 大幸薬品株式会社 骨芽細胞の細胞死阻害剤
DE102007029042A1 (de) 2007-06-21 2008-12-24 Analyticon Discovery Gmbh Pharmazeutische Zusammensetzung mit einem Trihydroxychromenone-Derivate
WO2010075282A1 (fr) * 2008-12-22 2010-07-01 University Of Washington Inhibiteurs moléculaires de la voie wnt/bêta-caténine

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
None *
See also references of WO2013034119A1 *

Also Published As

Publication number Publication date
US20160347782A1 (en) 2016-12-01
DE102011112496A1 (de) 2013-03-07
US20190085007A1 (en) 2019-03-21
WO2013034119A1 (fr) 2013-03-14

Similar Documents

Publication Publication Date Title
EP1299406B1 (fr) Derives de curcumine a solubilite dans l'eau amelioree vis-a-vis de la curcumine, et medicaments renfermant ces derives
DE69633502T2 (de) Procyanidin als den aktiven bestandteil enthaltende mittel gegen fettleibigkeit
DE60118019T2 (de) Zusammensetzung enthaltend hydroxyzitronensäure und garcinol zur gewichtsreduzierung
WO2013034119A1 (fr) Dérivés du 4-methylcatechol et utilisations desdits dérivés
DE60110438T2 (de) Zusammensetzungen enthaltend stilbenoide mit einer hypoglykämischen wirkung
DE60030568T2 (de) Withania somnifera zusammensetzung
EP1845957B1 (fr) Procede pour produire un extrait medicamenteux contenant des hydroxystilbenes
EP0501205B1 (fr) Moyens antiphlogistiques
DE3511609C2 (fr)
EP2069334B2 (fr) Dihydrochalcone du type aspalathine, extrait provenant du rooibos non fermenté et son procédé de production
DE10029770A1 (de) Verwendung von Curcuminen zur Behandlung von soliden Tumoren,insbesondere von Hirntumoren
DE60109018T2 (de) Kavalactone als Hemmer der TNF-alpha Produktion
DE60316298T2 (de) Steigerung der bioverfügbarkeit/bioeffektivität durch cuminum cyminum und dessen extrakte und fraktionen
DE2926463A1 (de) Spiroketaline und ihre verwendung
EP2533787B1 (fr) Utilisation de triglycosides d'isorhamnétine
KR100564383B1 (ko) 진세노사이드 유도체의 제조방법
DE60118625T2 (de) Stabilisierte ascorbinsäure -3- phosphat- derivate
DE2953223C2 (fr)
DE60219620T2 (de) L-ascorbinsäure-2-o-maleinsäure-a-tocopheroldiester-1-propanol addukt und verfahren zu dessen herstellung
EP1603583A2 (fr) Utilisation d'encens ou de ses produits d'hydrogenation en prevention et/ou traitement d'une ischemie cerebrale et/ou d'une lesion cerebrale traumatique
WO2003043622A1 (fr) Bicyclo[3.3.1]nonan-2,4,9-triones substituees utilisees en tant qu'agents pharmaceutiques
EP0443198B1 (fr) Diterpènes avec de l'activité immunomodulatrice
EP1385578B1 (fr) Utilisation de rutines et d'aescines pour traiter des troubles de la circulation sanguine des oreilles
DE3546505C2 (fr)
WO2003043966A2 (fr) Isomere de clusianon et son utilisation

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20140207

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20170626

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20200303